Study selection
Randomised placebo controlled trials (RCTs) of psychotropic medication in adult patients with well-defined borderline personality disorder were eligible for inclusion. Borderline personality disorder needed to be defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) third edition, DSM-III-Revised or DSM-IV. Studies that focused on pharmacotherapy in other DSM personality disorders were excluded. Studies with a primary focus on treatment of a comorbid Axis I disorder such as psychotic, affective or anxiety disorders were excluded. If the measurement of instrument could not be assigned properly, it was eliminated from analysis.
Outcomes of interest were cognitive-perceptual symptoms, impulsive behavioural dyscontrol, affective dysregulation (depressed mood, anxiety, anger, mood liability) and global functioning.
Antipsychotic medication used included flupentixol, thiothixene, trifluoperazine, haloperidol, olanzapine, aripiprazole, ziprasidone and quetiapine at various doses. Intervention duration varied from five weeks to 26 weeks. Settings included in-patient and outpatient clinics.
The authors did not state how many reviewers were involved in study selection.
Assessment of study quality
There was no formal validity assessment.
Data extraction
Data were extracted into a standard form. For continuous outcome measures, the mean symptoms scores and corresponding standard deviation (SD) or standard error (SE) were recorded. Where applicable, standard error was converted into standard deviation. Where outcomes were not fully reported, missing data were requested from the trial authors. Standardised mean differences (SMD) between groups that used active agents and placebo controls were calculated. Effect sizes were corrected for small sample sizes.
It appeared that more than one reviewer extracted data as the authors stated that any differences were resolved in consensus.
Methods of synthesis
A fixed-effect model was used to combine studies and calculate standardised mean differences with associated 95% confidence intervals (CIs). Where there was statistical variation (Cochrane's Q p<0.05) between studies a random-
